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General aim of this thesis 
This thesis includes both experimental and clinical work on SCS in chronic neuro-
pathic pain (NNP). In the experimental part of this thesis the first three research 
questions were explored in an animal model of NPP and SCS. The latter and clinical 
part of this thesis focuses on the fourth research question. 
The following research questions were addressed (see Chapter 1, Introduction 
page 20) and based on our research we are able to formulate the following answers: 
 
RQ 1. What is the current status and effectiveness of SCS in the treatment of NPP 
as related to its technical and anatomic aspects? 
SCS is a valuable therapy for neuropathic pain in CRPS-1 and FBSS that still has a 40 
% failure rate. In order to reach a possible future enhancement of the effectiveness 
of SCS therapy a greater understanding of the mechanism(s) and site(s) of action of 
SCS combined with a science based and effective use of technical aspects of SCS is 
needed. In Chapter 2 we summarized all data on technical aspects related to SCS as 
well as the computer modelling related to the physical and mathematical calcula-
tions of conductivity and tissue characteristics. From this we concluded that in order 
to enhance the effectiveness of SCS a combined translational research effort should 
be taken that is aimed at 
1. The search for clinical predictors of a successful outcome of SCS 
2. The development of a computer model that integrates new findings on the neu-
rophysiology, biochemistry and circuitry of SCS into a model that can be used to 
calculate optimal SCS settings. 
3. Experimental research in order to further elucidate the mechanisms of SCS. 
 
RQ 2 Are there signs or symptoms of neuropathic pain that may predict the out-
come of SCS in terms of pain relief? 
In Chapter 3 we report two important observations: Firstly the response to SCS 
differed with the severity of mechanical allodynia; mildly allodynic rats completely 
recovered to their baseline pre-injury sensory levels compared to moderate and 
severe allodynic animals which showed a partial and a non-response respectively. 
Secondly, mildly allodynic animals reached the optimal response twice as fast as 
moderately allodynic animals. These findings might be of clinical importance. 
 
RQ 3 Does SCS of the dorsal columns act via a segmental spinal mechanism? 
Our data in Chapters 4 and 5 demonstrate that SCS of the dorsal columns at the 
level where the injured fibres enter the spinal cord dorsal horn result in a much 
better pain relieving effect than SCS at more rostral levels. Furthermore, the in-
creased amount of c-Fos IR cells in the dorsal horns of allodynic rats after successful 
SCS indicates cellular activation at the level of stimulation. From this we conclude 
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that SCS in treatment of chronic neuropathic pain acts through a segmental spinal 
site of action. 
 
RQ 4 What is the long term (twelve year follow-up) effectiveness of SCS in CRPS-1 
in terms of pain relief and what are the frequency and nature of long-term com-
plications of this therapy. 
SCS for intractable CRPS-1 pain proves to be a valuable therapy with long term effi-
cacy (years) in about 40% of the patients (Chapter 6). Serious complications like 
infections and epidural haematomas did not occur in our study population. Surgical 
re-interventions are quite common and mostly comprise of battery changes and 
lead repositioning after dislocation. 
 
In experimental pain research the selection of an animal model is crucial. The use of 
animal models in studies on chronic pain has been under debate as translation of 
the results to the clinical situation if often of limited success (169). The limited pro-
gress in translating preclinical findings may have been caused by failure to recognize 
the limitations of different assessment methods, over interpretation of behavioural 
responses and failure to acknowledge which neural circuits are involved in the ex-
pression of specific behaviours (170). Nevertheless, an experimental animal model 
can be an important tool to study underlying mechanisms of disease and create or 
improve therapies, provided the animal model has enough clinical relevancy. It 
should be taken into account that studies on experimental SCS in (chronic) neuro-
pathic pain require a complex animal model which is basically consisting of two 
components; firstly, the induction of neuropathic pain and secondly the treatment 
with SCS. Whereas in our studies we focussed, clinically at the CRPS-1 patients (see 
Chapter 6) our animal model should meet the requirements needed. CRPS-1 is char-
acterized by sensory abnormalities, vascular abnormalities, oedema and sweating 
abnormalities and motor and trophic changes (171) (see also Chapter 1). The sen-
sory abnormalities consist of spontaneous (burning) pain that is disproportionate to 
any inciting event, touch evoked allodynia/hyperalgesia and cold allodynia (172). 
The development of CRPS-1 is likely to be caused by an aberrant inflammatory re-
sponse that causes central sensitization which then might contribute to pain. In-
creased concentrations of the inflammatory mediators interleukine (IL) -6 and IL-1β 
were reported in spinal fluid of chronic CRPS-1 patients (172,173). In contrast to 
CRPS-2, CRPS-1 is thought not to be preceded by a nerve lesion. Hence, from a clini-
cal point of view the animal models of sciatic nerve mononeuropathy as they are 
commonly used in research on SCS are more likely to mimic CRPS-2. Nevertheless 
experimental neuropathic pain models characterized by the absence of an axotomy 
of primary sensory neurons in the dorsal root have been described in literature, for 
instance; the Ventral Root Transection or VRT-model (174). In the VRT-model the 
ventral root fibres are lesioned which results in an inflammatory response and this 
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subsequently affects the uninjured dorsal root sensory afferents. A major limitation 
of this VRT-model is the bilateral presence of sensory abnormalities in contrast to 
the clinically observed unilateral symptoms in the CRPS-1 patients (172). Bilateral 
sensory abnormalities are noted only in very severe CRPS-1 patients (172). Other 
animal models that have been used to mimic CRPS-1 are the Chronic Post Ischemia 
Pain model (175), the tibia fracture (176) and the intra-arterial Substance-P injec-
tion model (177). Although these models do mimic CRPS-1 to some extend none of 
them have yet been tried in combination with SCS. Although some of these models 
may display symptoms that are similar to the symptoms seen in CRPS-1 it is impor-
tant to realize that CRPS-1, as mentioned before, is a multifactorial disease that is 
probably caused by environmental as well as genetic factors. Mailis and Wade pro-
vided evidence for a genetic basis of CRPS-1 (178). In order to provide a possible 
future animal model of CRPS-1 based on its genetic profile, the use of mice models 
may be more useful as the mouse genome displays an easy mutagenesis and 95% of 
the mouse genome is similar to that in humans (179,180). A functional SCS neuro-
pathic mouse model has already been introduced by Truin et al (103). 
 
Important factors in the choice of an animal model of neuropathic pain (CRPS-1) are 
reproducibility, time of onset of the pain symptoms and stability and duration of the 
symptoms over time. With this in mind, the partial ligation of the sciatic nerve or 
Seltzer model of neuropathic pain has a very good profile as the onset of mechani-
cal allodynia/hyperalgesia is almost immediate (hours), the duration of symptoms is 
reported to be months and this model is characterized by a response: non-response 
rate of about 70:30 (56). 
In view of the response to experimental nerve injury and development of neu-
ropathic symptoms genetic (181) as well as dietary factors (133,134) have been 
suggested to play an important role. 
Genetic differences in sensitivity to mechanical allodynia in rats is reported 
(182). However, little is known about the identity of predisposing genes. Recently 
the gene CACNG2 is shown to significantly affect the susceptibility to chronic pain 
following nerve injury. CACNG2 encodes for stargazin, a protein intimately involved 
in the trafficking of glutamatergic AMPA receptors (183). which forms a critical step 
in the central sensitization process (23,184). With respect to dietary factors mediat-
ing the response to nerve injury a study by Shir and co-workers reported that the 
presence of dietary phyto-estrogens in soy containing food reduced NPP symptoms 
in rats (133,134). However in our own experiments (Chapters 3,4 and 5) the Seltzer 
(56) rat model of neuropathic pain resulted in high response rates of mechanical 
allodynia even in the presence of phyto-estrogens in the food. As explained and 
discussed in Chapter 3 nerve ligation performed exactly at the site that is described 
in the paper by Seltzer (56) resulted in a high reproducibility and response rate. 
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Then with respect to the second component of our animal model: the SCS, it is im-
portant to stress that the Seltzer-model used is known to allow the study of a pain 
relieving effect of the SCS treatment (see Chapter 1). For example neuropathic pain 
induced by the Gazelius (185) photochemical sciatic nerve lesion model animals do 
not respond to SCS therapy without additional administration of intrathecal drugs. A 
recent experimental neuropathic pain model that also seems to respond poorly to 
SCS is the spared nerve injury model (SNI) (132). Commonly used successful animal 
models of mononeuropathy and experimental SCS are the partial ligation of the 
sciatic nerve (56) but also the Chronic Constriction Injury (CCI) of the sciatic nerve by 
Bennett and Xie (90). Despite all possible limitations the Seltzer model of chronic 
neuropathic pain has been shown to be very translational with respect to study and 
effects of SCS as related to CRPS type 1 patients: 
1. Analogy between experimental and clinical findings in pain relieving effect 
Both in clinical use of SCS in CRPS-1 patients as well as the experimental use of 
SCS in Seltzer injured animals resulted in similar proportions of responders (2/3) 
and non-responders (1/3). This is striking because we should take into account 
that different outcome measurements are used in experimental and clinical 
evaluation of the pain relieving effects. In the clinical setting pain reduction is 
measured by the VAS scores which relates to a reduction in spontaneous pain 
(49). The experimental results refer to a decrease in mechanical allodynia, as 
measured by an increase in withdrawal threshold to tactile stimuli with the von 
Frey test. 
2. Analogy between experimental and clinical findings in the mechanism underly-
ing non-response to SCS 
In various experimental neuropathic pain models, including the partial ligation 
of the sciatic nerve or Seltzer model, a loss of GABA and its synthesizing enzyme 
glutamate decarboxylase from the dorsal horn has been reported following 
nerve injury in rats (111,184,186,187). An important proposed mechanism un-
derlying the effect of SCS in neuropathic pain is the increase of extracellular 
GABA in the dorsal horn through the facilitation of the GABA-release (38,58). 
Whereas the responders to SCS were characterized by enhanced GABA-release 
in the spinal dorsal horn the non-responders did not (38,73). However, when ex-
tracellular GABA concentrations in non-responders to SCS were pharmacologi-
cally increased through the intrathecal application of sub effective doses of 
GABA analogues like gabapentin or pregabalin or through the application of the 
GABAB receptor agonist baclofen, these animals showed a marked decrease in 
withdrawal thresholds. Furthermore, intrathecal administration of a sub effec-
tive dose of the GABAA receptor agonist muscimol did not result in efficient re-
versal of SCS non-responders into responders (58,82,128). These findings were 
translated to the clinic where also neuropathic pain patients initially non-
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responding to SCS, did respond to SCS if co-treated with sub effective doses of 
intrathecally applied baclofen (83,188,189). 
3. Analogy between experimental and clinical findings and the prediction of the 
pain relieving effect SCS related to the severity of allodynia. 
Our experimental results as presented in Chapter 3 on the severity of allodynia 
and effect of SCS on the withdrawal response to tactile stimuli with the von Frey 
test were translated to the clinic. In Chapter 3 we report an inverse relationship 
between the severity of mechanical allodynia and the pain relieving effect of 
SCS: severe allodynic rats do not respond to SCS (Chapter 3; Figure 3). In analogy 
to this a follow-up study by van Eijs et al. (68) reported that brush evoked allo-
dynia may be a significant negative prognostic factor of SCS treatment outcome 
after 1 year in chronic CRPS-1 patients. 
 
In this thesis indirect evidence is provided that SCS mainly acts via a segmental spi-
nal mechanism (see Smits et al., 2009; 2011; Chapters 4 and 5). Based on the seg-
mental localization of the electrode (Smits et al., 2011, Chapter 4) as well as the 
local activation of cells in the dorsal horn of the spinal cord (71) (Chapter 5) it is now 
clear that in order to obtain a maximal effective pain relief the localization of the 
electrodes as related to the segmental spinal level is of the utmost importance. 
However, it should be noted that our data do not completely rule out a possible 
contribution of supraspinal elements. The latter is based on the fact that also a 
more rostral localization of the electrodes (i.e T11) still results in some pain relief. 
There is literature demonstrating the contribution of supraspinal centres based on 
lesioning of the dorsal columns rostral to the electrode (65,190). It is known that 
selective lesioning experiments focused at the dorsal columns are very complicated, 
highly variable in both size and impact and very difficult to qualify in particular at 
the behavioural level. The additional evidence we provide with respect to a SCS 
segmental spinal mechanism is a so-called repositioning experiment, which is similar 
to the paresthesia-steering in the clinic: In the same animal the repositioning of the 
electrode from T13 to only one segment rostral (T12) already resulted in a signifi-
cant reduction of the pain relieving effect in our experimental chronic neuropathic 
pain model. 
In view of the positioning of the electrode not only the segmental localization is 
of the utmost importance but also the medio-lateral positioning. Whereas laterali-
zation of the electrodes is indeed important to SCS-induced analgesia we always 
examined the medial-lateral position of the electrodes based on X-Ray. It is known 
that the clinical percutaneous circular leads allow for a lot of medial lateral move-
ment. In our experimental setting we used 1 mm wide platina-iridium plate elec-
trodes custom made by Medtronics (Bakken Research Centre, Maastricht, The 
Netherlands).Whereas the dimensions of our leads (width (1mm) and thickness 0.10 
mm) were specifically based on rat spinal cord anatomy and related to the dimen-
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sions of MRI images of the rat spinal cord, the electrodes exactly fit to the space 
above the dorsal columns without compression of the spinal cord. Macroscopic 
evaluation of the spinal cord tissue after SCS (as previously mentioned in a histo-
logical study (71) (see Chapter 5) allow the localization of the electrodes based on 
the presence of a sharply imprinted minimal brown coloured deposition of old 
blood and fibrin from the implantation operation on the dura mater. From this 
sharply edged print on the dura we concluded that the electrodes were fixed in one 
place at the midline where they initially are implanted. We suggest that the main 
reason for this fixation is related to the fact that the electrode is pushed to the 
arched bone at the dorsal side by the dura and that results in an evenly balanced 
pressure from the ventral side of the electrode by the underlying CSF underneath 
which will not allow easy lateral movement. Moreover, in our laboratory the wire of 
the SCS electrode is secured with histo-acryl tissue glue to the spine processes situ-
ated next to the area of burr hole which is exactly in the midline. This also minimizes 
the medial-lateral as well as the rostral-caudal movement. Although it might be 
suggested that a CT-scan is needed and results in a conclusive answer on the exact 
medio-lateral localization of the electrodes we like to indicate that the metal plates 
of the electrodes will probably produce a scatter in the image due to reflection of 
the metal, resulting in a deformed image of the electrode and it’s direct surround-
ings. The anterior posterior X-ray we used does mimic the clinical situation in a best 
possible way. Clinically the medial lateral position of the electrode is adjusted by 
“paraesthesia steering” which is not possible in animals, although our repositioning 
experiment (Chapter 4) comes close. 
The size of the experimental electrodes related to the dimensions of the spinal 
cord and spinal roots does not rule out a possible stimulation effect via the dorsal 
afferents. A electrophysiological study by Guan and colleagues (141) further sub-
stantiated this: they studied the effect of a bipolar electrical conditioning stimula-
tion of the dorsal column and lumbar dorsal roots on the response properties of the 
spinal wide dynamic range (WDR) neurons in rats after L5 spinal nerve injury. 
Whereas the conditioning stimulation intensity was set at the lowest current that 
evoked a peak antidromic sciatic Aβ-compound action potential without inducing an 
Aδ- or C-compound action potential they noted that both the dorsal column and the 
dorsal root conditioning stimulation significantly attenuated WDR neuronal re-
sponses to mechanical stimuli in nerve injured rats. Moreover they noted that 
stimulation of both dorsal columns and dorsal roots inhibited short-term neuronal 
sensitization (141). These findings indicate that dorsal root stimulation, due to the 
relatively large size of the electrodes in our rat model, still might form a serious 
complication in the experimental setting. On the other hand these electrophysio-
logical studies point to the fact that probably also in the clinical setting dorsal root 
stimulation in treatment of neuropathic pain might be effective as well. In view of 
the fact that, at least in the experimental setting it cannot be excluded that other 
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structures then the dorsal columns are involved and may account for the therapeu-
tic effect of SCS the term dorsal column stimulation may be replaced by the more 
neutral phrase “spinal axis stimulation”, as already suggested earlier (191). 
Whereas the WDR cells, located in the deeper dorsal horn layers are, based on 
the electrophysiological data (55,141) clearly involved in the mechanism underlying 
SCS induced pain relief, the question still remains how the activation of the large 
myelinated primary afferents in the dorsal columns finally results in modulating the 
incoming pain signal. The spinal nociceptive network and the relation with the mye-
linated primary afferents in the dorsal columns is presented in Chapter 2, Figure 1. 
In general SCS of the myelinated primary afferents is thought to induce changes at 
spinal levels as the balance of inhibitory and excitatory neurotransmitters in the 
dorsal horn is changed (58) (see Chapter 2). In addition several biochemical and 
pharmacological experimental studies on the mechanisms of action of SCS showed 
an alteration of the chemical transmission in the spinal dorsal horn (52,64,72,73). 
There is evidence that the neuropathic pain syndrome, described as peripheral 
hypersensitivity with allodynia and hyperalgesia, is a result of central sensitization. 
Central sensitization is a result of neurochemical changes in the pain transmission in 
the dorsal horn mainly due to an increased release of the excitatory neurotransmit-
ters glutamate and aspartate (74) and at the same time a loss of tonic GABA medi-
ated inhibition. Basically a decreased extracellular concentration of glutamate and 
at the same time an increased extracellular GABA-concentration have been noted 
after SCS (58,72) and this results in the suppression of hyperexcitable WDR neurons 
(55). 
The importance of central sensitization and the role of (phosphorylation of) the 
NMDA receptor during the pain relieving effect of SCS in chronic neuropathic rats 
was shown in a pharmacological study performed by Michiel Truin (66). It was al-
ready known that interference with the process of central sensitization through the 
antagonism of the NMDA receptor attenuates chronic neuropathic pain. The use of 
the non-competitive NMDA blocker ketamine has been shown to have analgesic 
effect on neuropathic pain in both experimental and clinical studies (110,192,193). 
A combined treatment of SCS and sub-effective dose of i.t. ketamine in non-
responders resulted in a significant reduction of the withdrawal threshold in all 
previous non-responders to SCS (66). 
As indicated in the Figure 1 (Chapter 2) the spinal dorsal horn has been re-
ported to contain a ‘silent’ circuit between low-threshold afferent fibres and No-
ciceptive Specific (NS) projection neurons located in lamina I. Although the composi-
tion of this circuit has been only partly described excitatory interneurons in the 
innermost part of lamina II, which express the γ-isoform of protein kinase C (PKC-γ) 
are suggested to be important (77) especially because PKC-γ interneurons are 
known to be activated via Aβ fibres signalling (79). In order to develop further in-
sights into the cellular components involved in the SCS mediated modulation of the 
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spinal nociceptive network neuro-anatomical studies might add. In a first attempt 
we studied the number of c-Fos-immunoreactive cells in the dorsal horn immedi-
ately after SCS (Chapter 3). Immediate early genes, like c-Fos, have been used as 
indirect markers of neuronal activity (144) and increases in the number of c-Fos 
immunoreactive cells have been reported a few hours to a few days after peripheral 
nerve injury (147). In our study we noted an increase in the number of c-Fos immu-
noreactive cells in the dorsal horn after SCS at the level of stimulation (Chapter 5). 
Further characterization of these c-Fos immunoreactive cells is needed. Whereas 
GABA-ergic inhibitory interneurons are predominantly located in spinal laminae 1-3 
(34) and their interference with nociceptive activation of pain signalling neurons has 
already been pointed out decennia ago (24) a double immunostaining of c-Fos with 
antibodies directed against the neurotransmitter GABA -is a logical first next step in 
analyzing the cellular components involved the mechanism underlying SCS mode of 
action (194). 
Another approach might be the in vivo imaging of metabolic activity of cells in 
neuropathic animals after SCS. Metabolic activity of cells can be visualized using 
flavoproteins: Mitochondrial oxidized flavoproteins have the ability to absorb blue 
spectrum photons. This causes an immediate emission of green spectrum photons, 
whose intensity (detected by a CCD camera) is a direct measure of neuronal meta-
bolic activity. 
The autofluorescent flavoprotein imaging (AFI) technique is an optical tech-
nique suitable for monitoring metabolic activity in the superficial areas of nervous 
tissue thereby studying cellular processes in vivo in the cerebellum (195) and cere-
bral cortex (196). Moreover using the AFI-technique it was possible to demonstrate 
simultaneously the temporal and spatial propagation of spinal nociceptive activity in 
vivo in the spinal cord dorsal horn (197). In a pilot study we investigated the effect 
of spinal cord stimulation on spinal dorsal horn metabolic activity in neuropathic 
rats in vivo (198). Our preliminary data showed a short-lasting, but strong reduction 
in AFI intensity relative to baseline in SCS animals, which was not observed in ani-
mals that underwent sham stimulation. These observations directly visualize the 
temporal and spatial extension of spinal hyperexcitability following nerve injury. At 
present we are analyzing the same animals used for AFI intensity measurements but 
now, after perfusion fixation, for double immunohistochemical analysis of the im-
mediate early gene c-Fos and the GABA synthesizing enzyme glutamate-
decarboxylase (GAD) in the dorsal horn(198). 
 
The latter and clinical part of this thesis focuses on the long term effectiveness of 
SCS in CRPS-1 patients based on a prospective (cohort) 12 year follow up study of 
SCS in CRPS-1 patients. Data on the long term outcome beyond five years of treat-
ment of SCS in CRPS-1 patients are sparsely available. As stabilization or improve-
ment of CRPS-1 only occurs early on in the disease, analysis of the efficacy of thera-
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peutic interventions in chronic CRPS-1 patients is therefore of the utmost impor-
tance. 
Future research 
Both in clinic and in the experimental setting chronic neuropathic pain is character-
ized by a wide variety of different grades of allodynia. The significant differences in 
pain relief in groups with different grades of allodynia after SCS in the Seltzer animal 
model (Chapter 3) did initiate a translational clinical study performed by van Eijs et 
al. (68). This clinical study showed that the presence of brush-evoked allodynia was 
associated with a lower chance (31 %) of achieving long-term (up to 1 year) pain 
reduction with SCS treatment, versus an 81% chance of pain reduction in patients 
without brush evoked allodynia. Hence the mean and maximum value of brush-
evoked allodynia proved to be statistically significant predictors of outcome (68). 
Despite this important translational finding future research should be aimed at the 
understanding of SCS and the process of central sensitization, as this is believed to 
be among the most important cellular changes present in chronic neuropathic pain. 
This then may lead to new clinical predictors on the effect of SCS in pain relief in 
neuropathic patients and finally result in an increased effectiveness of SCS. 
The wide variety of allodynia noted in the experimental model (Chapter 3) also 
shares a lot of analogy to the clinic of CRPS-1 patients and raises the issue of the 
relatively vague 1994 International Association for the Study of Pain (IASP) defini-
tion of CRPS-1 (2). There is a lack of agreement between the different diagnostic 
sets for CRPS I and this results in different clinical profiles leading to different thera-
peutic and study populations. This will slow down scientific development and ade-
quate treatment of CRPS-1(199). With respect to our findings on severity of allo-
dynia and the effect of SCS it may be useful to define a gradation of spontaneous 
pain and positive sensory signs (gain) CRPS-1 and mild, moderate and severe allo-
dynia. It may well be that the presence or absence of allodynia in CRPS-1 patients is 
based on differences in CRPS-1 pathophysiology, which finally result in a different 
pain-relief response to SCS. A study by Eberle et al (200) noted differences in clinical 
symptoms in patients with so-called warm and cold CRPS-1. This might indicate a 
difference in pathophysiology. Based on this study and the possible different patho-
physiological mechanisms in sub-populations of CRPS-1 patients the presence of 
allodynia and pinprick hyperalgesia, as signs of secondary hyperalgesia, indicate the 
involvement of central sensitization. A recent study in 692 CRPS-1 patients by de 
Boer et al (17) demonstrated that the pain and sensory signs in CRPS-1 tend to in-
crease in time thereby also pointing towards involvement of cellular modulation of 
the pain signal at different brain levels (central sensitization). From this the authors 
favour the development of a more mechanism based classification of CRPS-1 which 
ultimately should lead to a mechanism based (SCS)-treatment. We have shown that 
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the experimental Seltzer model is of use in the understanding of mechanisms un-
derlying SCS and thus can be of great use for future translational research on effec-
tiveness of SCS in neuropathic pain. 
 
 
